Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 21/74 ]
NASDAQ | Common Stock
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally.
The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications.
The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system.
The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders.
Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system.
It developing Talisman pulse generator and receiver for peripheral nerve stimulation.
The company was founded in 2011 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | 0.06 Increased by +20.00% | 0.03 Increased by +100.00% |
| Aug 6, 24 | 0.19 Increased by +35.71% | 0.07 Increased by +171.43% |
| May 7, 24 | 0.07 Increased by +126.92% | -0.07 Increased by +200.00% |
| Mar 12, 24 | 0.07 Increased by +216.67% | 0.02 Increased by +250.00% |
| Nov 7, 23 | 0.05 Decreased by -37.50% | -0.02 Increased by +350.00% |
| Aug 8, 23 | 0.14 Increased by +40.00% | 0.03 Increased by +366.67% |
| May 16, 23 | -0.26 Decreased by -750.00% | -0.15 Decreased by -73.33% |
| Mar 31, 23 | -0.06 Decreased by -123.08% | 0.05 Decreased by -220.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 138.96 M Increased by +15.04% | -4.82 M Increased by +33.94% | Decreased by -3.47% Increased by +42.58% |
| Jun 30, 24 | 151.22 M Increased by +10.32% | -23.99 M Decreased by -551.78% | Decreased by -15.87% Decreased by -490.80% |
| Mar 31, 24 | 129.46 M Increased by +8.73% | -4.57 M Increased by +95.43% | Decreased by -3.53% Increased by +95.80% |
| Dec 31, 23 | 135.42 M Increased by +7.62% | -6.10 M Increased by +86.41% | Decreased by -4.50% Increased by +87.38% |
| Sep 30, 23 | 120.79 M Decreased by -11.87% | -7.30 M Decreased by -330.02% | Decreased by -6.05% Decreased by -361.01% |
| Jun 30, 23 | 137.07 M Decreased by -2.32% | -3.68 M Increased by +54.07% | Decreased by -2.69% Increased by +52.97% |
| Mar 31, 23 | 119.06 M Increased by +1.51% | -100.02 M Decreased by -575.52% | Decreased by -84.01% Decreased by -565.49% |
| Dec 31, 22 | 125.83 M Decreased by -3.51% | -44.87 M Decreased by -12.23 K% | Decreased by -35.66% Decreased by -12.68 K% |